Are there any subgroups that benefit more/less of Palbociclib 1
st
line?
HR (95% CI)
Favors
PAL+LET
Favors
PCB+LET
“unable to identify a sub-group that does not benefit from the addition of
palbociclib”
All patients
ER
Rb IHC
Cyclin D
IHC
p16 IHC
0.0 0.5 1.0
1.5
Strengths
-
Central analysis including >85% patients
-
Candidate approach
-
Quantitative + Qualitative analysis
?
Ongoing studies:
-
CCND1 amplification and p16 loss by
FISH
-
Gene expression analyses of CDK2,
CDK4, CDK6, CCNE1, CCNE2, RB, and
p16
-
PgR by IHC and HER2 by FISH
Main limitations:
-
Limited numbers in some subgroups
-
Archival Tissue
Finn et al. ESMO 2016
Biomarker analysis
